Cost-Utility Analysis of Pegaspargase for the Treatment of Acute Lymphoblastic Leukemia in Greece.
Gourzoulidis GeorgeKoulentaki MariaKattamis AntonisBouzani MariaGiatra CharaChotzagiannoglou VassilikiBeletsi AlexandraKourlaba GeorgiaPublished in: Clinical drug investigation (2022)
The pegaspargase sequence was found to be less costly and more effective (in terms of QALYs) in relation to the L-asparaginase sequence, representing a dominant strategic option for Greek public payers in ALL.